title: [Anti-platelets without a bleeding risk: novel targets and strategies].
abstract: Anti-platelet agents such as aspirin, clopidogrel and antagonists of integrin αIIbβ3 allowed to efficiently reduce morbidity and mortality associated with arterial thrombosis. A major limit of these drugs is that they increase the risk of bleeding. During the last few years, several innovative anti-thrombotic strategies with a potentially low bleeding risk were proposed. These approaches target the collagen receptor glycoprotein (GP) VI, the GPIb/von Willebrand factor axis, the thrombin receptor PAR-1, the activated form of integrin αIIbβ3 or the ADP receptor P2Y1. While an antagonist of PAR-1 was recently marketed, the clinical proofs of the efficiency and safety of the other agents remain to be established. This review evaluates these new anti-platelet approaches toward safer anti-thrombotic therapies.
authors.affiliation: Atherothrombosis and Vascular Biology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Australie.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Schaff
authors.affiliation: UMR_S949, INSERM, Etablissement Français du Sang (EFS)-Alsace, Université de Strasbourg, Strasbourg, France.
authors.forename: Christian
authors.initials: C
authors.lastname: Gachet
authors.affiliation: UMR_S949, INSERM, Etablissement Français du Sang (EFS)-Alsace, Université de Strasbourg, Strasbourg, France.
authors.forename: Pierre Henri
authors.initials: PH
authors.lastname: Mangin
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods* / Q000639:trends; D012307:Risk Factors
chemical_list: D015507:Drugs, Investigational; D005343:Fibrinolytic Agents